CTOs on the Move

Allergene

www.allergen.com

 
Allergene is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.allergen.com
  • 1650 Borel Pl Ste 234
    San Mateo, CA USA 94402
  • Phone: 650.341.9808

Executives

Name Title Contact Details

Similar Companies

Diana Plants Sciences (Diana Group)

Diana Plants Sciences (Diana Group) is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allied Biotech

Allied Biotech is a Ijamsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. We currently have development pipelines in the fields of dermatology, ophthalmology, orthopedics, and stem cell therapy that highlight the capabilities of our novel drug products.

Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.